Document Detail

Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes.
MedLine Citation:
PMID:  12743153     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To determine whether pattern of WT1 gene expression is a useful marker for establishing prognosis and tracking disease progression in patients with myelodysplastic syndromes (MDS). PATIENTS AND METHODS: We performed a quantitative assessment of the WT1 transcript amount by real-time quantitative polymerase chain reaction (RQ-PCR) in 173 samples (131 bone marrow samples and 42 peripheral-blood samples) from 131 patients with MDS (79 patients with refractory anemia [RA], 31 with RA with excess blasts [RAEB], 18 with secondary acute myeloid leukemia [s-AML] evolved from MDS, and three with deletion of 5q as the sole cytogenetic abnormality). Values obtained were correlated with the blast percentage and International Prognostic Scoring System (IPSS) score. RESULTS: Sixty-five percent of BM and 78% of PB samples for RA and 100% of BM and PB samples of RAEB and s-AML expressed WT1 transcript amounts greater than the level observed in healthy volunteers. The degree of WT1 expression was highly correlated with the type of MDS, was much higher in RAEB and s-AML compared with RA, and increased during disease progression. Moreover, a significant correlation was found between WT1 expression levels, blast cell percentage, and the presence of cytogenetic abnormalities. Therefore, we found a significant correlation between the amount of WT1 transcripts and the IPSS score, which currently represents the most reliable risk index of disease progression available for MDS patients. CONCLUSION: WT1 is a useful molecular marker for risk assessment in MDS patients.
Daniela Cilloni; Enrico Gottardi; Francesca Messa; Milena Fava; Patrizia Scaravaglio; Marilena Bertini; Mauro Girotto; Carlo Marinone; Dario Ferrero; Andrea Gallamini; Alessandro Levis; Giuseppe Saglio;
Related Documents :
6949633 - Cytogenetic studies in adult acute leukemias.
3203293 - Breakpoint zone of bcr in chronic myelogenous leukemia does not correlate with disease ...
9714283 - Facial balance and harmony: an attainable objective for the patient with a high mandibu...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of clinical oncology : official journal of the American Society of Clinical Oncology     Volume:  21     ISSN:  0732-183X     ISO Abbreviation:  J. Clin. Oncol.     Publication Date:  2003 May 
Date Detail:
Created Date:  2003-05-13     Completed Date:  2003-05-27     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8309333     Medline TA:  J Clin Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1988-95     Citation Subset:  IM    
Division of Hematology and Internal Medicne, Department of Clinical and Biological Sciences, University of Turin, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Bone Marrow / metabolism
Case-Control Studies
DNA Primers
Disease Progression
Flow Cytometry
Gene Expression Regulation, Neoplastic
Leukemia, Myeloid / diagnosis,  genetics,  metabolism,  pathology
Myelodysplastic Syndromes / diagnosis*,  genetics,  metabolism,  pathology
Polymerase Chain Reaction
Regression Analysis
Tumor Markers, Biological / blood,  metabolism*
WT1 Proteins / blood,  metabolism*
Reg. No./Substance:
0/DNA Primers; 0/Tumor Markers, Biological; 0/WT1 Proteins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.
Next Document:  Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501...